Hebert LE, Scherr PA, Bienias JL, et al.Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol2003; 60:1119-1122.
2.
Sloane PD, Zimmerman S, Suchindran C, et al.The public health impact of Alzheimer’s disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health2002; 23:213-231.
3.
Brookmeyer R, Gray S, Kawas C.Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health1998; 88:1337-1342.
4.
Jarvik LF, La Rue A, Gokhman I, et al.Middle-aged children of Alzheimer parents, a pilot study: stable neurocognitive performance at 20-year follow-up. J Geriatr Psychiatry Neurol2005; 18:187-191.
5.
Jorm AF, Jolley D.The incidence of dementia: a meta-analysis. Neurology1998; 51:728-733.
6.
Jorm AF, Korten AD, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand1987; 76:465-479.
7.
Fratiglioni L, DeRonchi D, Aguero-Torres H.Worldwide prevalence and incidence of dementia. Drugs Aging1999; 15:365-375.
8.
General Accounting Office/Health Education Human Services-98-16. Alzheimer’s disease: estimates of prevalence in the United States. Washington, DC: General Accounting Office, 1998.
9.
Fratiglioni L, Launer LJ, Andersen K, et al.Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology2000; 54:S10-S15.
10.
Llacer A, Zunzunegui MV, Gutierrez PC, et al.Correlates of well-being of spousal and children carers of disabled people over 65 in Spain. Eur J Public Health2002; 12:3-9.
11.
Mittelman MS, Roth DL, Coon DW, Haley WE. Sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer’s disease. Am J Psychiatry2004; 161:850-856.
12.
Taylor DH Jr.Alzheimer’s disease and the family caregiver: the cost and who pays? N C Med J2005; 66:18-25.
13.
Wan TTH. Stressful life events, social support networks, and gerontological health. Lexington, Mass: Lexington Books, 1982.
14.
Crespo M, Lopez J, Zarit SH. Depression and anxiety in primary caregivers: a comparative study of caregivers of demented and nondemented older persons. Int J Geriatr Psychiatry2005; 20:591-592.
15.
Rasgon N, Jarvik L.Insulin resistance, affective disorders, and Alzheimer’s disease: review and hypothesis. J Gerontol A Biol Sci Med Sci2004; 59:178-183.
16.
Sapolsky RM. Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry2004; 56:137-139.
17.
Roberts JS, Cupples LA, Relkin NR, et al.Genetic risk assessment for adult children of people with Alzheimer’s disease: the Risk Evaluation and Education for Alzheimer’s disease (REVEAL) study. J Geriatr Psychiatry Neurol2005; 18:250-255.
18.
Zonderman AB. Predicting Alzheimer’s disease in the Baltimore Longitudinal Study of Aging. J Geriatr Psychiatry Neurol2005; 18:192-195.
19.
Ringman JM. What the study of persons at risk for familial Alzheimer’s disease can tell us about the earliest stages of the disorder: a review. J Geriatr Psychiatry Neurol2005; 18:228-233.
20.
Kukull WA, Ganguli M.Epidemiology of dementia: concepts and overview. Neurol Clin2000; 18:923-950.
21.
Farrer LA, Cupples LA, Haines JL, et al.APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, gender and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA1997; 278:1349-1356.
22.
Mayeux R, Saunders AM, Shea S, et al.Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. N Engl J Med1998; 338:506-511.
23.
Corder EH, Saunders AM, Strittmatter WJ, et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science2003; 261:921-923.
24.
Tsuang D, Bird DT. Genetics of dementia. In: Sadavoy J, Jarvik L, Grossberg G, Meyers B, eds. Comprehensive textbook of geriatric psychiatry. 3rd ed.New York: W. W. Norton and Company, 2004: 39-84.
25.
Swan GE, Lessov-Schlaggar CN, Carmelli D, et al.Apolipoprotein E ε4 and change in cognitive functioning in community-dwelling older adults. J Geriatr Psychiatry Neurol2005; 18:196-201.
26.
Gerlai R.Phenomics: fiction or the future? Trends Neurosci2002; 25:506-509.
27.
Freimer N, Sabatti C.The human phenome project. Nat Genet2003; 34:15-21.
28.
Breitner JC. Clinical genetics and genetic counseling in Alzheimer disease. Ann Intern Med1991; 115:601-606.
29.
van Dujin CM, Hofman A.Risk factors for Alzheimer’s disease: the EURODEM collaborative re-analysis of case-control studies. Neuroepidemiology1992; 11:106-113.
30.
Hebert LE, Scherr PA, Beckett LA, et al.Age-specific incidence of Alzheimer’s disease in a community population. JAMA1995; 273:1354-1359.
31.
Lautenschlager NT, Cupples LA, Rao VS, et al.Risk of dementia among relatives of Alzheimer’s disease patients in the MIRAGE study: what is in the store for the oldest old? Neurology1996; 46:641-650.
32.
Launer LJ, Andersen K, Dewey ME, et al.Rates and risk factors for dementia and Alzheimer’s disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology1999; 52:78-84.
33.
Liddel MB, Lovestone S, Owen MJ. Genetic risk of AD: advising relatives. Br J Psychiatry2001; 178:7-11.
34.
Silverman JM, Ciresi G, Smith CJ, et al.Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiatry2005; 62:565-573.
35.
van Duijn CM, Stijnen T, Hofman A.Risk factors for Alzheimer’s disease: overview of the EURODEM collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol1991; 20:S4-S12.
36.
Huang W, Qiu C, von Strauss E, et al.APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol2004; 61:1930-1935.
37.
Zandi PP, Breitner JC, Anthony JC. Is pharmacological prevention of Alzheimer’s a realistic goal? Expert Opin Pharmacother2002; 3:365-380.
38.
Schmelzer KR, Kubala L, Newman JW, et al.Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A2005; 102:9772-9777.
39.
Durga J, van Tits LJ, Schouten EG, et al.Effect of lowering of homocysteine levels on inflammatory markers: a randomized controlled trial. Arch Intern Med2005; 165:1388-1394.
40.
Corrada MM, Kawas CH, Hallfrisch J, et al.Reduced risk of Alzheimer’s disease with high folate intake: the Baltimore Longitudinal Study. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association2005; 1:11-18.
41.
Morris MC, Evans DA, Bienias JL, et al.Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. Arch Neurol2005; 62:641-645.
42.
Frenkel D, Maron R, Burt DS, Weiner HL. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest2005; 10.1172/JCI23241.
43.
Goni F, Sigurdsson EM. New directions towards safer and effective vaccines for Alzheimer’s disease. Curr Opin Mol Ther2005; 7:17-23.
44.
Travis J.Saving the mind faces high hurdles. Science2005; 309:731-734.
45.
Jarvik LF. Age is in—is the wit out? In: Samuel D, Algeri S, Gershon S, Grimm VE, Toffano G, eds. Aging of the brain Vol. 22. New York: Raven Press, 1983: 1-8.
46.
Lee HG, Perry G, Moreira PI, et al.Tau phosphorylation in Alzheimer’s disease: pathogen or protector?Trends Mol Med2005; 11:164-169.
47.
Nimmerjahn A, Kirchoff F, Helmechen F.Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science2005; 308:1314-1318.
48.
Matsuyama SS, Jarvik LF. Hypothesis: microtubules, a key to Alzheimer disease. Proc Natl Acad Sci U S A1989; 86:8152-8156.
49.
White L, Small BJ, Petrovitch H, et al.Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neurol2005; 18:224-227.
50.
Jarvik LF, Matsuyama SS, Chui H, et al.Autopsy diagnoses of Alzheimer’s disease: independent reviews and clinical implications. Int J Geriatr Psychiatry1995; 10:505-510.
51.
McKhann G, Drachman D, Folstein M, et al.Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984; 34:939-944.
52.
Silverman DH, Small GW, Chang CY, et al.Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA2001; 286:2120-2127.
53.
Mortimer JA, Borenstein AR, Gosche KM, Snowdon DA. Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol2005; 18:218-223.
54.
Gatz M, Fiske A, Reynolds CA, et al.Performance on neurocognitive tests by co-twins to dementia cases compared to normal control twins. J Geriatr Psychiatry Neurol2005; 18:202-207.
55.
McArdle JJ, Small BJ, Bäckman L, Fratiglioni L.Longitudinal models of growth and survival applied to the early detection of Alzheimer’s disease. J Geriatr Psychiatry Neurol2005; 18:234-241.
56.
Manly JJ, Schupf N, Tang M-X, Stern Y.Cognitive decline and literacy among ethnically diverse elders. J Geriatr Psychiatry Neurol2005; 18:213-217.
57.
Sager MA, Hermann B, La Rue A.Middle-aged children of persons with Alzheimer’s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer’s Prevention. J Geriatr Psychiatry Neurol2005; 18:245-249.
58.
Coats M, Morris JC. Antecedent biomarkers of Alzheimer’s disease: the Adult Children Study. J Geriatr Psychiatry Neurol2005; 18:242-244.
59.
Au R, Seshadri S, Wolf PA, et al.New norms for a new generation: cognitive performance in the Framingham offspring cohort. Exp Aging Res2004; 30:333-358.
60.
Yip AG, McKee AC, Green RC, et al.APOE, vascular pathology, and the AD brain. Neurology2005; 65:259-265.
61.
Kuller LH, Lopez OL, Jagust WJ, et al.Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology2005; 64:1548-1552.
62.
Carlson MC, Zandi PP, Plassman BL, et al.Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study. Neurology2000; 57:2210-2216.
63.
Breitner JCS, Welsh KA, Gau BA, et al.Alzheimer’s disease in the National Academy of Sciences-National Research Council Registry of Aging Twin Veterans. III. Detection of cases, longitudinal results, and observations on twin concordance. Arch Neurol1995; 52:763-771.
64.
Hendrie HC, Ogunniyi A, Hall KS, et al.Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA2001; 285:739-747.
65.
Blazer DG, Fillenbaum GG, Gold DT, et al.APOE epsilon4 as a predictor of subjective quality of life in a biracial older person community sample. J Aging Health2003; 15:645-660.
66.
Daly E, Zaitchik D, Copeland M, et al.Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol2000; 57:675-680.
Small GW, Ercoli LM, Silverman DHS. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc Natl Acad Sci U S A2000; 97:6037-6042.
69.
Ercoli L, Siddarth P, Harrison T, et al.Similar neurocognitive performance of adults with and without a history of parental Alzheimer’s disease: a pilot study. J Geriatr Psychiatry Neurol2005; 18:208-212.
70.
Grundman M, Petersen RC, Ferris SH, et al.Mild impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol2004; 61:59-66.
71.
Bäckman L, Jones S, Berger AL, et al.Cognitive impairment in preclinical Alzheimer’s disease: a meta-analysis. Neuropsychology2005; 19:520-531.
72.
Stagnitti MN. Top 10 outpatient prescription medicines ranked by utilization and expenditures for the U.S. community population, 2002. Statistical Brief #60. December 2004. Agency for Healthcare Research and Quality, Rockville, Md. Available at: http://www.meps.ahrq.gov/papers/st60/stat60.pdf.